Investing in high quality development shares is a superb technique for producing outsized returns over the long run. Valued at a market cap of lower than $400 million, Profound Medical (TSX:PRN) is a commercial-stage medical system firm that’s poised to develop at a speedy tempo.
It develops and markets incision-free therapeutic programs for the image-guided ablation of diseased tissue in North America and Europe. Profound Medical’s flagship TULSA-PRO system makes use of MRI-guided robotic transurethral thermal ultrasound and temperature suggestions controls to exactly ablate focused areas of prostate tissue, whether or not malignant or benign.
The corporate additionally affords Sonalleve, an MRI-guided thermal remedy platform that treats uterine fibroids, adenomyotic tissue, bone metastasis ache, osteoid osteoma, and benign tumours.
Immediately, PRN inventory is down 70% from all-time highs, permitting you to purchase the dip and profit from outsized returns over the subsequent three years.
The bull case for investing on this small-cap TSX inventory
Profound Medical delivered an 87% income bounce within the third quarter because the medical system firm continues to achieve traction with its MRI-guided prostate remedy know-how. The Toronto-based agency introduced in $5.3 million for the three months ended September 30, up sharply from $2.8 million in the identical interval final yr.
The corporate now has 70 TULSA-PRO programs put in at hospitals and remedy facilities, with one other 93 websites in superior phases of the gross sales pipeline. Chief Government Arun Menawat stated the agency is on observe to hit at the very least 75 installations by year-end.
Income from recurring procedures reached $4.1 million within the quarter, whereas one-time gear gross sales added $1.2 million. Gross margins improved to 74.3% from 63.1% a yr earlier. It reported a internet lack of $8 million, or $0.26 per share, down from $9.4 million within the third quarter of 2024. Profound ended Q3 with nearly $25 million in money, offering it with liquidity for the subsequent three quarters.
Profound Medical affords remedy that makes use of ultrasound waves guided by MRI imaging to destroy prostate tissue with out surgical incisions.
Sufferers sometimes go away the hospital the identical day with minimal bleeding or extreme unintended effects. Medicare now covers the process following approval of a Class One billing code earlier this yr.
Some business insurers are additionally beginning to reimburse on a case-by-case foundation, with funds starting from $25,000 to $65,000 per remedy.
Profound launched new software program within the quarter that cuts process time for treating benign prostate enlargement, a situation affecting tens of millions of males.
- The improve permits medical doctors to finish therapies in 60 to 90 minutes, making it aggressive with different therapies.
- Firm president Mathieu Burtnyk stated the know-how can even goal each most cancers and benign tissue in a single session.
- The agency is testing broader purposes past prostate care. Its Sonalleve system makes use of targeted ultrasound to deal with uterine fibroids and is being studied for pancreatic most cancers.
Chief Monetary Officer Rashed Dewan stated the corporate expects to cut back money burn as income grows and ultimately attain a money stream constructive standing. Administration maintained its 70% income development goal for 2025.
Is that this Canadian inventory undervalued?
Analysts monitoring Profound Medical forecast income to extend from $15.2 million in 2024 to $142 million in 2029. Furthermore, it’s forecast to report a free money stream (FCF) of $63 million in 2028, in comparison with an outflow of $32.5 million in 2025.
If the TSX inventory is priced at 20 occasions trailing FCF, which is kind of low cost, it may greater than triple over the subsequent three years.